Begin main content

Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women

Last updated: September 10, 2019
Project Number: HE0023-000
Product Line: Technology Review
Research Type: Drug
Result type: Report
Expected Completion Date: March 11, 2020

Osteoporosis is a systemic skeletal disease characterized by a loss of bone mass and an increased risk of fragility fractures. Osteoporosis is highly prevalent, affecting an estimated 1.5 million Canadians over 40 years of age. Fractures associated with osteoporosis commonly occur in vertebral sites, but also occur in non-vertebral sites. They are associated with significant costs, diminished quality of life, and mortality, as well as an increased risk of future fractures.

In Canada, different classes of drugs are indicated for osteoporosis. Of interest to this project are four bisphosphonates (alendronate, risedronate, etidronate, and zoledronic acid), denosumab, and teriparatide. These drugs have been available for decades, are widely used, and have a significant budget impact. This proposed project will evaluate the relative clinical effectiveness and safety of the drugs used in the treatment and prevention of osteoporosis in postmenopausal women.


Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.